{"schema_version":"secwatch.filing_event.v1","accession":"0001662774-25-000031","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.254093+00:00","generated_at":"2026-05-21T16:21:12.511820+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026","bullets":["63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.","Early enrollment conclusion by end of June would provide ~80% power for primary endpoint.","Cash and investments $31.6M; net loss Q1 2025 of $15.0M ($0.34 per share).","Topline results expected early 2026; NDA/MAA submissions planned H2 2026 if positive.","All 19 study sites activated; slower enrollment cited due to challenging academic site environment."],"urls":{"canonical":"https://secwatch.observer/filing/0001662774-25-000031","json":"https://secwatch.observer/filing/0001662774-25-000031.json","markdown":"https://secwatch.observer/filing/0001662774-25-000031.md","text":"https://secwatch.observer/filing/0001662774-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/0001662774-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000166277425000031/qncx-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:21:12.511820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}